Loading...
Docoh

VectivBio Holding (VECT)

VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).

VECT stock data

Analyst ratings and price targets

Last 3 months

Calendar

7 Apr 22
12 Aug 22
31 Dec 22
Quarter (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
13F holders Current Prev Q Change
Total holders 19 7 +171.4%
Opened positions 12 0 NEW
Closed positions 0 19 EXIT
Increased positions 3 1 +200.0%
Reduced positions 1 3 -66.7%
13F shares Current Prev Q Change
Total value 109.87M 61.45M +78.8%
Total shares 28.94M 20.45M +41.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
Orbimed Advisors 5.33M $25.11M +8.7%
Novo Holdings A/S 3.38M $15.92M NEW
CHI Advisors 3.08M $14.53M +15.3%
Bpifrance Participations 2.81M $0 0.0%
Bpifrance 2.81M $13.22M NEW
Versant Venture Capital V 2.79M $0 0.0%
Citadel Advisors 2.72M $12.8M +0.1%
Eventide Asset Managment 2.34M $10.99M 0.0%
Cormorant Asset Management 2.08M $9.79M -6.2%
Tekla Capital Management 756.5K $3.56M NEW
Largest transactions Shares Bought/sold Change
Novo Holdings A/S 3.38M +3.38M NEW
Bpifrance 2.81M +2.81M NEW
Tekla Capital Management 756.5K +756.5K NEW
Orbimed Advisors 5.33M +427.2K +8.7%
CHI Advisors 3.08M +408.9K +15.3%
Driehaus Capital Management 393.37K +393.37K NEW
UBS UBS Group AG - Registered Shares 262.4K +262.4K NEW
Cormorant Asset Management 2.08M -138.28K -6.2%
BAC Bank Of America 85.48K +85.48K NEW
Canaan Partners XI 37.05K +37.05K NEW

Financial report summary

?
Competition
Takeda Pharmaceutical

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
Proxies
No filings